Author(s): Mohammed J Manna, Murtadha S Jabur, Haider Raheem Mohammad, Haidar A Abdulamir

Email(s): h_al_attar@yahoo.com

DOI: 10.52711/0974-360X.2022.00032   

Address: Mohammed J Manna1, Murtadha S Jabur2, Haider Raheem Mohammad3, Haidar A Abdulamir4*
1College of Dentistry, Mustansiriyah University, Baghdad, Iraq.
2College of Pharmacy, National University for Science and Technology, Nasiriyah, Iraq.
3College of Pharmacy, Mustansiriyah University, Baghdad, Iraq.
4College of Pharmacy, Almaaqal University, Basrah, Iraq.
*Corresponding Author

Published In:   Volume - 15,      Issue - 1,     Year - 2022


ABSTRACT:
Objectives: to study the oculo- hypotensive effect of non-selective phosphodiestrase inhibitor aminophylline. Methods: The study was conducted on fifteen albino rabbits (2.5–2.8 Kg) and model of acute ocular hypertension was obtained by 5% glucose water administration at 15ml/kg through the marginal vein of the rabbit’s ear. Aminophylline was dissolved in vehicle of phosphate buffer saline and diluted to desired concentration as 0.5%. Phosphate buffer saline solution also served as control. The left eye of rabbit was received one drop of aminophylline (0.5%) on the other hand the right eye treated by the vehicle and considered as control parameter. The pressure measurement was recorded at 15, 30, 45, 60, 90, 120, 135, 150 and 165 min after drug instillation. Results: After 30 minutes of topical 0.5% aminophylline administration the normal tension of the eye remain unchanged. However topical 0.5% aminophylline eye drop significantly (p < 0.05) successes in the decrease of the acute elevation of ocular pressure due to 5% glucose infusion. Moreover, in this study aminophylline pretreatment has the ability to facilitating the returns of the IOP to normal levels Conclusions: Topical administration of aminophylline (0.5%) significantly prevent acute rise in the ocular pressure induced by 5% glucose administration. The IOP lowering effect of aminophylline can be considered as potential antiglaucoma drug.


Cite this article:
Mohammed J Manna, Murtadha S Jabur, Haider Raheem Mohammad, Haidar A Abdulamir. The potential effect of topical aminophylline on acute glaucoma model. Research Journal of Pharmacy and Technology. 2022; 15(1):197-0. doi: 10.52711/0974-360X.2022.00032

Cite(Electronic):
Mohammed J Manna, Murtadha S Jabur, Haider Raheem Mohammad, Haidar A Abdulamir. The potential effect of topical aminophylline on acute glaucoma model. Research Journal of Pharmacy and Technology. 2022; 15(1):197-0. doi: 10.52711/0974-360X.2022.00032   Available on: https://rjptonline.org/AbstractView.aspx?PID=2022-15-1-32


REFERENCES:
1.    Weinreb RN, Aung T, Medeiros FA. The pathophysiology and treatment of glaucoma: a review. JAMA. 2014; 311(18): 1901-11.
2.    Heijl A, Leske MC, Bengtsson B, Hyman L, Bengtsson B, Hussein M; Early Manifest Glaucoma Trial Group. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol. 2002; 120(10): 1268-79.
3.    Matloub S.The effect of topical administration of sildenafil in acute ocular hypertension model in rabbits. Journal of the Faculty of Medicine Baghdad. 2011; 53(3): 317-319.
4.    Jonas JB, Aung T, Bourne RR, Bron AM, Ritch R, Panda-Jonas S. Glaucoma. Lancet. 2017; 390(10108): 2183-2193.
5.    Palaksha MN, Mani TT, Manjunatha E, Kumar gps. Comparative study of In-Vivo effects of Glipizide and Metformin HCl on plasma concentration of Aminophylline in healthy rabbits. Asian J. Pharm. Res. 2020; 10(2): 62-66.
6.    Meena SS. Drug Interaction of Aminophylline and Salbutamol Induced extreme Tachycardia in Chronic Obstructive Pulmonary Diseases - A Case Report. Research J. Pharm. and Tech 2019; 12(8): 3896-3898.
7.    Schmidt D, Dent G, Rabe KF. Selective phosphodiesterase inhibitors for the treatment of bronchial asthma and chronic obstructive pulmonary disease. Clin Exp Allergy. 1999 Jun;29 Suppl 2: 99-109.
8.    Barnes PJ. Histone deacetylase -2- and airway disease . the advance respiratory disease 2009; 5(3): 235-243.
9.    Chiou GC. Review: effects of nitric oxide on eye diseases and their treatment. J Ocul Pharmacol Ther. 2001; 17(2): 189-98.
10) Bredt DS, Snyder SH. Nitric oxide: a physiologic messenger molecule. Annu Rev Biochem. 1994; 63: 175-95.
10.    Xue W, Du S, Li Y, Huang K. [Pressure influence on mRNA expression and protein synthesis of inducible nitric oxide synthetase in bovine trabecular meshwork cell]. Zhonghua Yan Ke Za Zhi. 2000; 36(4): 295-8.
11.    Lipton SA, Choi YB, Pan ZH, Lei SZ, Chen HS, Sucher NJ, Loscalzo J, Singel DJ, Stamler JS. A redox-based mechanism for the neuroprotective and neurodestructive effects of nitric oxide and related nitroso-compounds. Nature. 1993; 364(6438): 626-32.
12.    Radi R, Beckman JS, Bush KM, Freeman BA. Peroxynitrite-induced membrane lipid peroxidation: the cytotoxic potential of superoxide and nitric oxide. Arch Biochem Biophys. 1991; 288(2): 481-7.
13.    Radi R, Beckman JS, Bush KM, Freeman BA. Peroxynitrite oxidation of sulfhydryls. The cytotoxic potential of superoxide and nitric oxide. J Biol Chem. 1991; 266(7): 4244-50.
14.    Ischiropoulos H, Zhu L, Chen J, Tsai M, Martin JC, Smith CD, Beckman JS. Peroxynitrite-mediated tyrosine nitration catalyzed by superoxide dismutase. Arch Biochem Biophys. 1992; 298(2): 431-7.
15.    Beckman JS, Chen J, Ischiropoulos H, Crow JP. Oxidative chemistry of peroxynitrite. Methods Enzymol. 1994; 233: 229-40.
16.    Saccà SC, Pascotto A, Camicione P, Capris P, Izzotti A. Oxidative DNA damage in the human trabecular meshwork: clinical correlation in patients with primary open-angle glaucoma. Arch Ophthalmol. 2005; 123(4): 458-63.
17.    Izzotti A, Saccà SC, Cartiglia C, De Flora S. Oxidative deoxyribonucleic acid damage in the eyes of glaucoma patients. Am J Med. 2003; 114(8): 638-46.
18.    Panchal SS, Mehta AA, Santani DD. Effect of potassium channel openers in acute and chronic models of glaucoma. Taiwan J Ophthalmol. 2016; 6(3): 131-135.
19.    Shah GB, Sharma S, Mehta AA, Goyal RK. Oculohypotensive effect of angiotensin-converting enzyme inhibitors in acute and chronic models of glaucoma. J Cardiovasc Pharmacol. 2000; 36(2): 169-75.
20.    Sugiyama T, Oku H, Ikari S, Ikeda T. Effect of nitric oxide synthase inhibitor on optic nerve head circulation in conscious rabbits. Invest Ophthalmol Vis Sci. 2000; 41(5): 1149-52.
21.    Zaidi SAH, Thakore N, Singh S, Guzman W, Mehrotra S, Gangaraju V, Husain S. Histone Deacetylases Regulation by δ-Opioids in Human Optic Nerve Head Astrocytes. Invest Ophthalmol Vis Sci. 2020; 61(11): 17.
22.    Vapaatalo H, Kotikoski H, Oksala O. Role of nitric oxide in the regulation of intraocular pressure: a possibility for glaucoma treatment. Expert Review of Ophthalmology 2010; 5(6): 751–758.
23.    Dawson VL, Dawson TM, Bartley DA, Uhl GR, Snyder SH. Mechanisms of nitric oxide-mediated neurotoxicity in primary brain cultures. J Neurosci. 1993; 13(6): 2651-61.
24.    Husain S, Abdul Y, Singh S, Ahmad A, Husain M. Regulation of nitric oxide production by δ-opioid receptors during glaucomatous injury. PLoS One. 2014; 9(10): e110397.
25.    Li JM, Fenton RA, Cutler BS, Dobson JG Jr. Adenosine enhances nitric oxide production by vascular endothelial cells. Am J Physiol. 1995; 269(2 Pt 1): C519-23.
26.    Landells LJ, Jensen MW, Orr LM, Spina D, O'Connor BJ, Page CP. The role of adenosine receptors in the action of theophylline on human peripheral blood mononuclear cells from healthy and asthmatic subjects. Br J Pharmacol. 2000; 129(6): 1140-4.
27.    Sansone GR, Matin A, Wang SF, Bouboulis D, Frieri M. Theophylline inhibits the production of nitric oxide by peripheral blood mononuclear cells from patients with asthma. Ann Allergy Asthma Immunol. 1998; 81(1): 90-5.
28.    Pinazo-Duran MD, Shoaie-Nia K, Zanon-Moreno V, Sanz-Gonzalez SM, Del Castillo JB, Garcia-Medina JJ. Strategies to Reduce Oxidative Stress in Glaucoma Patients. Curr Neuropharmacol. 2018; 16(7): 903-918.

Recomonded Articles:

Research Journal of Pharmacy and Technology (RJPT) is an international, peer-reviewed, multidisciplinary journal.... Read more >>>

RNI: CHHENG00387/33/1/2008-TC                     
DOI: 10.5958/0974-360X 

0.38
2018CiteScore
 
56th percentile
Powered by  Scopus


SCImago Journal & Country Rank


Recent Articles




Tags


Not Available